Cardiac injury and chronic heart diseases often result in irreversible loss of cardiomyocytes, impaired vascularization, and progressive decline in cardiac performance. RevAge is developed to address these pathological processes by promoting tissue repair and improving the cardiac microenvironment.

Therapeutic Rationale

Umbilical cord–derived MSCs possess potent regenerative and paracrine properties that make them well-suited for cardiac repair and functional recovery. RevAge targets multiple mechanisms involved in myocardial damage.

• • Reduction of inflammation and fibrosis within damaged cardiac tissue
• • Promotion of angiogenesis and improved blood supply to ischemic regions
• • Secretion of cardioprotective and pro-survival factors
• • Support of myocardial repair and functional tissue remodeling

Potential Benefits

RevAge is being developed to provide meaningful clinical benefits for patients with cardiac impairment, including:

• • Improvement in cardiac function and pumping efficiency
• • Reduction in symptoms associated with heart failure
• • Enhanced exercise tolerance and physical capacity
• • Improved quality of life and long-term cardiac resilience

Development Focus

RevAge is part of RCT’s regenerative cardiology research pipeline. Ongoing development efforts focus on safety evaluation, biological activity, and translational readiness to support future clinical studies in cardiac indications.